Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer.
Dustin A Deming
https://pubmed.ncbi.nlm.nih.gov/39752885/Actively Recruiting
Led by Amgen · Updated on 2026-09-03
450
Participants Needed
291
Research Sites
186 weeks
Total Duration
Researchers are evaluating treatments for participants with metastatic colorectal cancer who have a specific KRAS p.G12C mutation and have not received prior treatment. The study compares progression-free survival between two groups one receiving sotorasib, panitumumab, and FOLFIRI, and the other receiving FOLFIRI with or without bevacizumab-awwb. This is a phase 3 randomized trial aiming to understand which combination better manages the disease. Participants in one group take sotorasib daily as an oral tablet while receiving panitumumab and FOLFIRI every two weeks through intravenous infusions. The other group receives FOLFIRI every two weeks, with or without bevacizumab-awwb, also given by intravenous infusion every two weeks. The study treatments continue according to these schedules to compare their effects. Throughout the trial, participants will undergo assessments to measure progression-free survival using RECIST v1.1 criteria for up to approximately three years. Additional outcomes like overall survival, response rates, duration of response, and safety events are monitored for up to five years. Researchers will collect blood samples to measure sotorasib levels during early treatment cycles. Participants are closely observed through scheduled visits and tests to evaluate treatment effects and safety over the study duration.
CONDITIONS
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
A
Amgen Call Center
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Amgen
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Investigational combination (within trial) | Active comparator (within trial) | Current standard of care (external) |
|---|---|---|---|
| What it is | Investigational triplet regimen combining an oral KRAS p.G12C inhibitor (sotorasib), an anti‑EGFR antibody (panitumumab), and standard FOLFIRI chemotherapy | Comparator consisting of FOLFIRI chemotherapy with or without the anti‑VEGF antibody bevacizumab‑awwb | Common first‑line regimens include FOLFIRI or FOLFOX combined with bevacizumab or EGFR inhibitors depending on KRAS mutational status |
| Role in trial | Investigational treatment arm | Active comparator arm | Represents usual first‑line treatment outside the trial |
| Primary use | Treatment of KRAS p.G12C‑mutated metastatic CRC in treatment‑naïve setting | Treatment of metastatic CRC using FOLFIRI backbone with or without bevacizumab | Established first‑line chemotherapy regimens for metastatic CRC |
| How it is given or performed | Sotorasib taken orally daily, panitumumab and FOLFIRI given via intravenous infusion every two weeks | FOLFIRI given via intravenous infusion every two weeks, may include bevacizumab‑awwb IV Q2W | Chemotherapy administered IV typically every two weeks plus intravenous targeted antibody (bevacizumab or EGFR inhibitor) based on biomarker status |
| Regulatory status | Under investigation in clinical trial | FOLFIRI and bevacizumab‑awwb are approved regimens in metastatic colorectal cancer | Widely approved first‑line chemotherapy with targeted agents for metastatic CRC |
| Evidence status | Efficacy being evaluated in treatment‑naïve KRAS p.G12C mutant mCRC; early data from refractory cohorts show promising activity | Standard chemotherapy efficacy established in multiple trials | Standard first‑line regimens have known efficacy in unselected KRAS‑mutated mCRC |
| Important risks | Potential for additive toxicities including rash, diarrhea, stomatitis, hepatotoxicity as seen with sotorasib plus panitumumab combinations | Known FOLFIRI related toxicities (e.g., neutropenia, diarrhea) and those of bevacizumab | Risks associated with chemotherapy plus targeted agents include infusion reactions, cytopenias, hypertension, and skin reactions |
| Important limitations | Efficacy in treatment‑naïve setting not yet established; prior activity seen only in refractory patients and combination adds complexity | Limited effectiveness of FOLFIRI backbone in KRAS p.G12C patients; lack of mutation‑directed therapy | Standard regimens are not mutation‑specific and outcomes remain poor in KRAS mutant mCRC |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit
Duration - Up to approximately 3 years
Participants receive either sotorasib daily with panitumumab and FOLFIRI every two weeks, or FOLFIRI with or without bevacizumab-awwb every two weeks through intravenous infusions.
IV infusions every 2 weeks; daily oral medication for sotorasib group
Duration - Up to approximately 5 years
Participants are monitored for progression-free survival and other outcomes using RECIST v1.1 criteria for up to 3 years, with additional safety and survival follow-up up to 5 years.
Regular visits for assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Dustin A Deming
https://pubmed.ncbi.nlm.nih.gov/39752885/Amgen
Lead Sponsor